Loading…
Cardiff Oncology, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -78.9% over 5Y.
today you would have $186.19▼ -81.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 22 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.81 | $4.34 | $1.48 | $1.40 | $6.01 | $17.99 | $1.24 | $3.18 | $22.32 | $151.20 | $388.80 | $309.60 | $413.28 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PYPDPolyPid Ltd. | $5.07 | — | 19.1x | — | -243.59% | $102.98M |
| PLYXPolaryx Therapeutics, Inc. | $2.06 | — | 9.4x | — | -96.56% | $102.68M |
| LNSRLENSAR, Inc. | $8.30 | 41.5x | 6.8x | — | 357.30% | $101.97M |
| CCLDCareCloud, Inc. | $2.49 |
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Company description provided by Yahoo Finance.
| $498.96 |
| $237.60 |
| $224.64 |
| $324.00 |
| $142.56 |
| $289.44 |
| $470.88 |
| $794.88 |
| $1,728.00 |
| P/S | 240.1x | 324.0x | 422.7x | 135.5x | 162.0x | 725.0x | 1821.2x | 51.8x | 33.8x | 33.9x | 170.6x | 513.7x | 370.2x | 418.5x | 240.1x | 137.5x | — | — | — | — | — | — | — |
| P/B | 3.3x | 4.2x | 3.5x | 0.9x | 0.6x | 1.9x | 5.2x | 1.7x | 1.3x | 2.6x | 3.3x | 3.3x | 12.4x | 5.3x | 49.9x | — | — | — | — | — | — | — | — |
| EPS | -$0.69 | -$0.95 | -$0.93 | -$0.89 | -$0.73 | -$1.08 | -$2.80 | -$8.26 | -$51.76 | -$98.64 | -$87.12 | -$63.36 | -$50.40 | -$64.08 | -$16.56 | — | — | — | — | — | — | — |
| Profit margin | -6651.68% | -7732.04% | -6651.68% | -8492.01% | -10026.94% | -7880.50% | -5275.14% | -6709.74% | -4351.07% | -4928.09% | -10287.75% | -8781.98% | -5112.99% | -4555.88% | -2567.91% | -868.94% | — | — | — | — | — | — | — |
| ROE | -163.24% | -101.02% | -54.77% | -59.42% | -36.40% | -20.15% | -15.06% | -224.48% | -163.24% | -382.82% | -198.32% | -56.41% | -171.57% | -57.92% | -533.23% | — | — | — | — | -631.52% | -225.37% | -168.32% | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| 35.6x |
| 6.1x |
| — |
| 21.75% |
| $105.81M |
| SEERSeer, Inc. | $1.80 | — | 0.4x | — | -26.45% | $99.67M |
| COYACoya Therapeutics, Inc. | $4.59 | — | 2.5x | — | -60.54% | $107.67M |